PV Bulletin

‘Box-ticking’ consultations scrapped to speed up delivery

The scrapping of box-ticking consultations will lead to accelerated decision-making processes that apply across various regulatory frameworks impacting how multiple organizations operate.

Primary source: Open Government Licence v3.0

Translated From French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

PV Impact Brief

Urgency: HighConfidence: high

What changed

The guidance has changed to scrap ‘box-ticking’ consultations, which were previously required during regulatory review processes. This modification will lead to accelerated decision-making within the regulatory landscape.

Why it matters

By speeding up delivery timelines, organizations can respond more swiftly to emerging safety signals, regulatory changes, and market dynamics, contributing to better patient safety outcomes.

Action needed

PV teams should update SOPs regarding consultation processes and decision-making timelines in line with the new guidance to enhance operational efficiencies.

Relevant for
Regulatory Intelligence LeadQPPVPV Quality Lead
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 10, 2026

Full briefing

Practical implication

PV teams should update SOPs regarding consultation processes and decision-making timelines in line with the new guidance to enhance operational efficiencies.

This change eliminates unnecessary consultations in regulatory frameworks, streamlining processes and enhancing the efficiency of decision-making across multiple organizations.

What changed: The guidance has changed to scrap ‘box-ticking’ consultations, which were previously required during regulatory review processes. This modification will lead to accelerated decision-making within the regulatory landscape.

Why it matters: By speeding up delivery timelines, organizations can respond more swiftly to emerging safety signals, regulatory changes, and market dynamics, contributing to better patient safety outcomes.

Practical implication: PV teams should update SOPs regarding consultation processes and decision-making timelines in line with the new guidance to enhance operational efficiencies.

View original source

  • Source: MHRA - News and communications
  • Published at source: 2026-09-10T00:00:00.000Z
  • Discovered by monitor: 2026-09-10T21:49:32.281Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Guidance#Source-ingestion#Regulator-monitor#Uk#Gov.uk#Translated From French

Related updates for your role

publicEuropean Medicines Agency · European Union · Updated Sep 11, 2026

Implementation of ICH M12 Guideline on Drug Interaction Studies

Urgency: High

PV teams should update SOPs related to DDI study design and regulatory compliance to align with the ICH M12 guidelines. Additionally, workflows regarding gastrointestinal interactions will need revision following forthcoming guidelines addressing these gaps.

Signal ManagementInspection ReadinessRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 10, 2026

New Draft Guidelines for Clinical Investigation of Medicinal Products for Migraine and Cluster Headache

Urgency: High

PV teams should prepare to review and update relevant SOPs and workflows to incorporate feedback mechanisms and timelines associated with the new guidelines. Ensure monitoring of the consultation period and prepare for adjustments based on feedback.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 10, 2026Translated From Spanish

Beta Release of Product Management Service (PMS) Public API Changes Data Access Protocols

Urgency: High

PV teams need to update workflows and SOPs to incorporate the new PMS public API access protocols. This includes designing processes for monitoring user data access and ensuring compliance with the terms of use.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicFDA · USA · Updated Sep 11, 2026

Modernizing Bioequivalence Approaches for Topical and Transdermal Products

Urgency: High

PV teams should update their workflows, especially those related to regulatory intelligence monitoring, to incorporate insights from the workshop and adjust their compliance controls to align with the new FDA guidance on bioequivalence for topical and transdermal drugs.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward